Jovanovska Janeva, Elena
Preferred name
Jovanovska Janeva, Elena
Official Name
Jovanovska Janeva, Elena
Main Affiliation
21 results
Now showing 1 - 10 of 21
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, LEUKOTRIENE RECEPTOR ANTAGONISTS IN MANAGING SEVERE UNCONTROLLED ASTHMA(European Medical Group, 2017-08-03); ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, IL-33 in patients with severe uncontrolled allergic asthma(European Respiratory Society, 2017-09); ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Analysis of Plasma Concentrations of Theophylline in Smoking and nonsmoking Patients with asthma(Scientific Foundation SPIROSKI, 2015-12-15); - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Incidence of respiratory symptoms and allergic diseases in adolescent smokers in Former Yugoslav Republic of Macedonia (FYROM)(European Publishing, 2017-05-25); ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Correlation between plasma levels of IL-33 and Vitamin D in patients with severe uncontrolled allergic asthma(European Respiratory Journal, 2017-09); ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Relationship between Vitamin D, Inflammation and Lung Function In Patients with Severe Uncontrolled Asthma(Scientific Foundation SPIROSKI, 2017-12-15); ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Biomarkers of Inflammation in Peripheral Blood during Treatment with Inhaled Corticosteroids in Patients with Asthma(ID-Design/Scientific foundation SPIROSKI, 2016-12-23); ; ; Debreslioska, AngelaBACKGROUND: The main attribute of asthma is inflammation, which leads to airway remodelling, bronchial hyper-reactivity and reversible or partly reversible airway obstruction. According to GINA, asthma is a chronic inflammatory disorder of the airways in which many cells play a role, in particular, mast cells, eosinophils (Eo), and T lymphocytes. Many cells and mediators take part in creating the asthmatic inflammatory reaction, but eosinophils play a central role.AIM: The aim of this study was to show the values of biological inflammatory markers (IL-5, Eo, and ECP) during treatment with ICS by non-invasive methods.MATERIAL AND METHODS: This study includes 30 patients of the Pulmonology and Allergology Clinic, Skopje, with confirmed asthma, treated with ICS. In all of the patients, we followed Eo count, ECP and IL-5 in peripheral blood at the beginning of the study, after 2 and six months treatment. Following the parameters during treatment with ICS we registered changes in all of the tested parameters.RESULTS: Our results show high level of the tested biomarkers at the beginning of the study, IL-5 in all patients (100%), Eosinophils in 80%, and ECP in 90% of the asthmatics. Following the parameters during treatment with ICS we registered changes in all of the tested parameters.CONCLUSIONS: Our conclusion is that the ICS objectively suppress the inflammatory reaction in asthma and the biologic markers (IL-5, Eo and ECP), which we have followed, can measure the accomplished effect. They could be used in everyday practice, not only as diagnostic parameters but also as valid therapeutic guides in the treatment of asthma. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Evaluation of IL-8 and MEF25-75 in patients with severe COPD who were treated with combined therapy of ICSs / LABAs plus tiotropium bromide(Europian Respiratory Society, 2013); - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Leukotriene receptor antagonist (LTRA) added to regular preventive therapy: inhaled corticosteroids and longacting beta agonists (ICS/LABA) in patients with severe uncontrolled asthma(Macedonian Pharmaceutical Association, 2020-10-29); ; ; ; Goseva, Zlatica - Some of the metrics are blocked by yourconsent settings
Item type:Publication, ROLE AND CLINICAL SIGNIFICANCE OF IL-33 IN PATIENTS WITH ASTHMA(Macedonian Medical Association / Walter DeGruyter, 2017); ; Goseva, ZlaticaIntroduction. Asthma is a chronic inflammatory disease of the airways in which many cells play a role with secreting a variety of mediators responsible for the clinical manifestation of asthma. It is assumed that IL-33 is one of the earliest-released mediators and can orchestrate the immune cascade of the disease. The aimof this study was to examine the role and clinical significance of IL-33 as a new and insufficiently explored mediator of inflammation in patients with uncontrolled moderate asthma. Methods. The study included 87 patients with asthma. Serum IL-33 was measured in all patients by ELISA method. The obtained data were statistically analyzedusing the Kolmogorov-Smirnov and ShapiroWilk's test. Qualitative data were presented in absolute and relative numbers, and quantitative data were presented with measures of descriptive statistics. Statistically significant values were considered for p <0.05. Results. Majority of included patients were female (75.86%). The average age of patients was 42.3±15.9 years. The results of IL-33 in all patients were significantly increased compared to the reference value of IL-33 which is 0 pg/ml. The average values of IL-33 ranged from 6.47±29.3 and they were insignificantly higher in the group with female patients compared to males (p=0.27), and insignificantly correlated with age (p=0.26). Conclusion. Even though a limited number of studies have explored the IL-33, results have shown higher serum level of IL-33 in asthma patients compared to healthy people, emphasizing the fact that IL-33 is an attractive candidate for targeted therapy and prognosis in asthma patients.
- «
- 1 (current)
- 2
- 3
- »